Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies. The research, published October 21, 2025, in Nature Biotechnology, demonstrates how CRISPRoff and CRISPRon can reprogram a patient’s own T cells for therapeutic purposes without the cell toxicity and DNA damage associated with traditional gene editing approaches.

Estonia's obesity rate has been steadily climbing and so have scientific efforts to understand why. New study, published in Nature Communications, takes a closer look at the genes behind body weight and how they might point toward future treatments for obesity.

For decades, scientists have sought a single "obesity gene."

Doctors and researchers at the University of Pittsburgh and UPMC have developed a new treatment for epilepsy patients who don't respond to medication and aren’t candidates for surgery. Their approach, published today in Nature Communications, uses deep brain stimulation (DBS) that is tailored to each patient's unique brain wiring.

Epilepsy affects more than 50 million people worldwide, and about a third of those do not respond to medication.

A clinical trial from Wake Forest University School of Medicine shows that two widely available medications, the diabetes drug empagliflozin (Jardiance) and intranasal insulin, safely improve brain health in people with mild cognitive impairment and early Alzheimer's disease. The study, published in Alzheimer’s & Dementia, the journal of the Alzheimer's Association, marks the first time empagliflozin has been tested in non-diabetic patients with Alzheimer's disease. The results show promising effects on memory, brain health and brain blood flow.

Plant-based materials have traditionally been used to treat a variety of viral infections. Now, researchers have found that cardamom seed extract, as well as its main bioactive ingredient, 1,8-cineole, can have potent antiviral effects through its ability to enhance the production of antiviral molecules known as type I interferons via nucleic acid 'sensors' inside cells.

Plant-based treatments have traditionally been used to treat a wide range of diseases, including viral infections. Medicinal plants and herbs have been a rich source of 'bioactive' compounds (i.e. compounds that have a biological effect), which have been used by pharmaceutical companies in antiviral products.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder marked by hyperglycemia. Acarbose is a potent glycosidase inhibitor widely used in the clinical treatment of T2DM. However, acarbose-preferred glucosidase (Apg) in K. grimontii TD1 degrades acarbose to acarviosine-glucose (M1) and acarviosine (M2), affecting its efficiency.

In a study published in Nature Communications, a research team led by GU Yang from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, along with collaborators, revealed the detailed molecular mechanism of Apg hydrolyzing acarbose.

Researchers at UBC Okanagan have uncovered how plants produce mitraphylline, a rare natural compound that may help fight cancer.

Mitraphylline belongs to a small group of plant molecules called spirooxindole alkaloids. These compounds have unusual "twisted" ring structures and are known for their strong effects, like fighting tumours and inflammation.